Phase 1 Metastatic Clinical Trials

583 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 120 of 583 trials

Recruiting
Phase 1Phase 2

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Phase 1Phase 2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled11 locationsNCT07226986
Recruiting
Phase 1Phase 2

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca152 enrolled104 locationsNCT06996782
Recruiting
Phase 1Phase 2

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer
National Cancer Institute (NCI)60 enrolled1 locationNCT06149481
Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med LLC48 enrolled4 locationsNCT05283330
Recruiting
Phase 1

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Metastatic Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma
Alnylam Pharmaceuticals158 enrolled23 locationsNCT06600321
Recruiting
Phase 1Phase 2

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled29 locationsNCT07206056
Recruiting
Phase 1Phase 2

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute35 enrolled1 locationNCT07214298
Recruiting
Phase 1

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI)43 enrolled23 locationsNCT05687110
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

Advanced Solid TumorMetastatic Solid Tumor
Ipsen102 enrolled11 locationsNCT07213830
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Metastatic Solid TumorLocally Advanced Solid Tumor
Ipsen114 enrolled12 locationsNCT07213817
Recruiting
Phase 1Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast CancerEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma+1 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 1

In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

Colorectal Cancer MetastaticLung Metastases
University Health Network, Toronto10 enrolled1 locationNCT05611034
Recruiting
Phase 1Phase 2

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmMetastatic Colorectal Carcinoma+2 more
National Cancer Institute (NCI)30 enrolled22 locationsNCT05803382
Recruiting
Phase 1

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal Adenocarcinoma+1 more
National Cancer Institute (NCI)43 enrolled26 locationsNCT05685602
Recruiting
Phase 1Phase 2

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Advanced Solid TumorMetastatic Solid Tumor
Artios Pharma Ltd181 enrolled12 locationsNCT05898399
Recruiting
Phase 1Phase 2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Gastric CancerAdvanced Solid TumorNon-small Cell Lung Cancer+4 more
AstraZeneca70 enrolled15 locationsNCT06147037
Recruiting
Phase 1Phase 2

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Lung CancerMelanomaMetastatic Lung Cancer+2 more
Obsidian Therapeutics, Inc.208 enrolled9 locationsNCT06060613